FluxMPS™ RPMI 1640 Medium, High Glucose & 25mM HEPES w/o L-Glutamine: 1X Liquid
FluxMPS™ RPMI 1640 Medium, High Glucose & 25mM HEPES w/o L-Glutamine: 1X Liquid
FluxMPS™ DCP-RPMIGH-Q1X is a Microfluidics Suitable, ultra-filtered RPMI 1640 formulation engineered for organ-on-a-chip (OoC)[1] and microphysiological system (MPS) platforms. A quadruple-stage train (0.1 µm ×2 + 0.04 µm ×2) reaches a 0.04 µm final cut-off, five times finer than the 0.22 µm membranes used for conventional sterile filtration. High glucose (4500 mg/L) and 25 mM HEPES are paired with a 23.8 mM sodium bicarbonate system; L-Glutamine is intentionally omitted for user-controlled supplementation.
- High glucose (4500 mg/L) RPMI 1640 base dual-buffered with 25 mM HEPES and 23.8 mM sodium bicarbonate
- L-Glutamine intentionally omitted from the formulation — add fresh at time of use
- Quadruple-stage filtration train (0.1 µm ×2 + 0.04 µm ×2) reaching a 0.04 µm final polish
- Endotoxin release specification: < 0.05 EU/mL (LAL, USP <85>)
- Manufactured under an ISO 13485:2016 quality management system with full lot traceability
- Contains sodium pyruvate (110 mg/L) as an alternate carbon/energy source for metabolic flexibility
- Phenol red sodium salt included (5.3 mg/L) for visual pH monitoring
- Custom pH, glucose, HEPES, salts and nutrient modifications available on request
- Glucose4500.000 mg/L (High Glucose)
- L-GlutamineNone added (w/o L-Glutamine; user-supplemented)
- Sodium Pyruvate110.000 mg/L
- pH (USP <791>)7.4
- Osmolality (USP <785>)Contact for specification
- Endotoxin (USP <85>)< 0.05 EU/mL
- FiltrationQuadruple-stage: 0.1 µm ×2 + 0.04 µm ×2
- Storage2–8°C, protect from light
- Shelf Life12 months from date of manufacture, unopened
- ShippingCold pack
Available sizes: 500 mL, 1000 mL
Engineered where standard media fails
Conventional 0.22 µm–filtered media passes mycoplasma, subvisible particulates, and endotoxin fragments that confound sensitive cell assays.
Microchannel-safe purity
0.04 µm final filtration; USP <788> Method 1 particulate compliance. Engineered for microfluidic and organ-on-a-chip channels sensitive to particulate accumulation.
Total metabolic control
Defined high-glucose formulation with sodium pyruvate for precise control of carbon sources and metabolic inputs; L-Glutamine is intentionally omitted for user-controlled supplementation.
Ultrapure-grade water
Type 1 water, 18.2 MΩ·cm resistivity, with controlled trace-metal and organic-carbon (TOC) content at the manufacturing source.
Low background for imaging
Ultra-low particulate baseline supports confocal microscopy, biosensor measurements, and live-cell imaging workflows on-chip.
Rich, stable nutrient profile
40 verified ingredients per lot, presented across 3 composition tabs. Full CAS traceability. Micro-batch precision manufacturing.
Customization on demand
pH, nutrient concentrations, HEPES, and component modifications available. Contact support@diagnocine.com.
Quadruple-stage filtration system
Four serial filtration stages — two dedicated 0.1 µm prefilter + 0.04 µm final-filter pairs run in series — reaching a final 0.04 µm polish, engineered for microfluidic channels and organ-on-a-chip (OoC) platforms sensitive to particulate accumulation and mycoplasma contamination.
-
1
0.1 µm Prefiltration I — Large Particulate & Debris Removal
Removes large aggregates, cell debris and protein clumps; protects the first dedicated 0.04 µm final-filter cartridge.
-
2
0.04 µm Final Filtration I — Mycoplasma-Retentive Polish
Sub-mycoplasma-retentive membrane (mycoplasma range 0.2–0.3 µm); filtration control, not a per-lot mycoplasma test result.
-
3
0.1 µm Prefiltration II — Redundant Protection
Second dedicated prefilter, protecting the second 0.04 µm final-filter cartridge; independent redundancy, not a re-polish of Stage 2 effluent.
-
4
0.04 µm Final Filtration II — Polish & Aseptic Fill
Ultimate polishing filter ahead of aseptic fill & finish; final product QC release gate.
Performance vs. conventional media
© Diagnocine® — DCP-RPMIGH-Q1X
OoC and MPS Applications
FluxMPS™ DCP-RPMIGH-Q1X delivers Microfluidics Suitable, ultra-filtered purity for organ-on-a-chip and microfluidic applications.[3]
Automated Bioreactors & Robotics
An optional 0.01 µm (10 nm) ultra nano-filtered MPS Grade variant is available on request for automated bioreactors and robotic perfusion systems.
- Total Particulate Exclusion: 10 nm filtration removes nanoparticulate aggregates that foul automated systems
- Valve & Sensor Protection: Reduces micro-fouling risk in automated perfusion and recirculation systems
- Extended Perfusion Stability: Supports consistent nutrient delivery over long-duration culture runs
Inquiry Required: Contact support@diagnocine.com to request the 0.01 µm MPS Grade variant.
Micro Physiological System (MPS) & Chip
0.04 µm filtered media for organ-on-a-chip, tissue-on-a-chip, and body-on-a-chip applications where low-particulate media helps prevent channel fouling.
Cancer Cell Lines & Metabolic Research
High-glucose, pyruvate-supplemented formulation supports NCI-60 cancer lines and Warburg effect metabolic studies.[10]
iPSC-Derived Models
Ultra-clean base for iPSC differentiation protocols requiring defined, low-particulate media.
Endothelial & Primary Cells
Low-particulate formulation suited to primary cell and endothelial monolayer studies on-chip.
Metabolic Flux Analysis
Defined high-glucose, pyruvate-containing formulation supports ¹³C isotope tracing and NMR metabolomics workflows. Not compatible with Agilent Seahorse XF assays, which require bicarbonate-free, phenol red-free medium.
Microscopy & Optical Sensing
Ultra-low particulate background for confocal microscopy, biosensor measurements, and TEER monitoring on-chip.
Analytical release specifications
Every lot released against the full specification matrix. Certificate of Analysis available: support@diagnocine.com.
| Parameter | Specification |
|---|---|
| Formulation | [+] Sodium Bicarbonate, [+] Phenol Red, [+] HEPES (25mM), [+] Calcium, [+] Magnesium, [+] Glucose (High), [+] Sodium Pyruvate, [-] L-Glutamine |
| Appearance | Red-colored, clear solution (phenol red present) |
| pH USP <791> | 7.4 |
| Osmolality USP <785> | Contact for specification |
| Glucose | 4500.000 mg/L |
| L-Glutamine | None added (w/o L-Glutamine) |
| Sodium Pyruvate | 110.000 mg/L |
| Phenol Red | Present (5.300 mg/L, phenol red sodium salt) |
| Parameter | Specification |
|---|---|
| Endotoxin USP <85> BET | < 0.05 EU/mL |
| Sterility USP <71> | No growth / 14 days |
| Mycoplasma | 0.1 µm / 0.04 µm mycoplasma-retentive filtration (not tested per lot) |
| Particulate ≥10 µm USP <788> Method 1 | NMT 25/mL |
| Particulate ≥25 µm USP <788> Method 1 | NMT 3/mL |
| Water purity | Type 1, 18.2 MΩ·cm |
| Manufacturing std. ISO | ISO 13485:2016 |
| Fill environment | ISO Class 5 (Class 100) |
| Parameter | Specification |
|---|---|
| Storage temperature | 2–8°C, protect from light |
| Freeze-thaw | Do not freeze |
| Shelf life | 12 months from date of manufacture, unopened |
| Shipping condition | Cold pack |
| CO₂ requirement | 5% CO₂ recommended; 25 mM HEPES supplements the 23.8 mM sodium bicarbonate system for added pH stability outside the incubator |
| Parameter | Specification |
|---|---|
| Raw material grade | Reagent / cell culture grade |
| Traceability | Full lot traceability per ISO 13485 |
| Manufacturing QMS ISO | ISO 13485:2016 certified |
| UNSPSC | 41116155 | Molecular biology and cell culture growth media | UNv260801 |
| Regulatory alignment | 21 CFR Part 820 (QMSR) aligned |
| Production method | Micro-batch, per-lot QC release |
| Intended use | Research Use Only (RUO) |
Full composition (mg/L)
RPMI 1640 Medium, High Glucose & 25mM HEPES w/o L-Glutamine: 1X Liquid — 40 verified ingredients per lot, presented across 3 composition tabs, with CAS numbers for raw-material traceability. All ingredients from the original formulation are preserved.
| Component | CAS Number | mg/L |
|---|---|---|
| INORGANIC SALTS | ||
| Calcium nitrate tetrahydrate | 13477-34-4 | 100.000 |
| Magnesium sulfate anhydrous | 7487-88-9 | 48.840 |
| Potassium chloride | 7447-40-7 | 400.000 |
| Sodium bicarbonate | 144-55-8 | 2000.000 |
| Sodium chloride | 7647-14-5 | 6000.000 |
| Sodium phosphate dibasic anhydrous | 7558-79-4 | 800.000 |
| Component | CAS Number | mg/L |
|---|---|---|
| AMINO ACIDS | ||
| Glycine | 56-40-6 | 10.000 |
| L-Arginine hydrochloride | 1119-34-2 | 241.000 |
| L-Asparagine | 70-47-3 | 50.000 |
| L-Aspartic acid | 56-84-8 | 20.000 |
| L-Cystine dihydrochloride | 30925-07-6 | 65.200 |
| L-Glutamic acid | 56-86-0 | 20.000 |
| L-Histidine hydrochloride monohydrate | 5934-29-2 | 20.960 |
| L-Hydroxyproline | 51-35-4 | 20.000 |
| L-Isoleucine | 73-32-5 | 50.000 |
| L-Leucine | 61-90-5 | 50.000 |
| L-Lysine hydrochloride | 657-27-2 | 40.000 |
| L-Methionine | 63-68-3 | 15.000 |
| L-Phenylalanine | 63-91-2 | 15.000 |
| L-Proline | 147-85-3 | 20.000 |
| L-Serine | 56-45-1 | 30.000 |
| L-Threonine | 72-19-5 | 20.000 |
| L-Tryptophan | 73-22-3 | 5.000 |
| L-Tyrosine Disodium Salt | 69847-45-6 | 28.830 |
| L-Valine | 72-18-4 | 20.000 |
| Component | CAS Number | mg/L |
|---|---|---|
| VITAMINS | ||
| Choline chloride | 67-48-1 | 3.000 |
| D-Biotin | 58-85-5 | 0.200 |
| D-Ca-Pantothenate | 137-08-6 | 0.250 |
| Folic acid | 59-30-3 | 1.000 |
| Niacinamide | 98-92-0 | 1.000 |
| Pyridoxine hydrochloride | 58-56-0 | 1.000 |
| Riboflavin | 83-88-5 | 0.200 |
| Thiamine hydrochloride | 67-03-8 | 1.000 |
| i-Inositol | 87-89-8 | 35.000 |
| p-Amino benzoic acid (PABA) | 150-13-0 | 1.000 |
| OTHERS | ||
| D-Glucose | 50-99-7 | 4500.000 |
| Glutathione reduced | 70-18-8 | 1.000 |
| HEPES | 7365-45-9 | 5958.000 |
| Phenol red sodium salt | 34487-61-1 | 5.300 |
| Sodium Pyruvate | 113-24-6 | 110.000 |
ISO 13485 Manufacturing & Compliance
Every batch of FluxMPS™ DCP-RPMIGH-Q1X is manufactured under a certified ISO 13485:2016 QMS with full lot traceability and multi-parameter QC release testing.
ISO 13485:2016 QMS
Full quality management system with documented procedures, deviation control, and CAPA. Every lot traceable from raw material to final release.
Ultrapure Type 1 Water
18.2 MΩ·cm resistivity, with controlled trace-metal and organic-carbon (TOC) content at the manufacturing source.
ISO Class 5 Fill & Finish
Final aseptic filling in ISO Class 5 (Class 100) cleanroom, immediately following the final filtration stage.
Micro-Batch Precision
Small-batch manufacturing with per-lot QC release. Every batch tested independently — not pooled or blended across lots.
Endotoxin USP <85> BET
LAL assay per batch. Release specification: < 0.05 EU/mL; assay sensitivity 0.005 EU/mL.
Particulate USP <788> Method 1
Light obscuration particulate analysis. NMT 25/mL at ≥10 µm; NMT 3/mL at ≥25 µm.
Osmolality USP <785>
Osmolality verified per lot using vapor pressure or freezing-point depression osmometry per USP <785>.
Documentation / CoA
Full Certificate of Analysis available per lot. Includes all QC parameters, test dates, and raw material lot numbers. Request: support@diagnocine.com.
- Endotoxin — LAL assay, USP <85> Bacterial Endotoxins Test; assay sensitivity 0.005 EU/mL; release specification < 0.05 EU/mL
- pH, osmolality, conductivity, appearance and clarity
- Sterility
How DCP-RPMIGH-Q1X compares
FluxMPS™ versus conventional 0.22 µm filtered media for OoC and MPS applications.
| Parameter | DCP-RPMIGH-Q1X (FluxMPS™) | Conventional 0.22 µm Filtered | Standard Alternative |
|---|---|---|---|
| Grade | Microfluidics Suitable | Standard grade | Standard grade |
| Formulation | [+] Sodium Bicarbonate, [+] Phenol Red, [+] HEPES, [+] Calcium, [+] Magnesium, [+] Glucose (High), [+] Sodium Pyruvate, [-] L-Glutamine | Standard RPMI 1640 | Standard RPMI 1640 |
| Final filtration pore size | 0.04 µm | 0.22 µm | 0.22 µm |
| Number of filtration stages | 4 stages (0.1µm ×2 + 0.04µm ×2) | 1 stage | 1–2 stages |
| Mycoplasma-retentive filtration | check_circle | cancel | cancel |
| Endotoxin (release specification) | FluxMPS™ — < 0.05 EU/mL | Corning classical liquid media — < 0.25 EU/mL Sigma-Aldrich DMEM complete medium — ≤ 2 EU/mL Gibco classical DMEM — Not specified (recorded per lot) |
|
| USP <788> Method 1 particulate compliance | check_circle | cancel | cancel |
| Water quality | Type 1, 18.2 MΩ·cm | Type 2 typical | Type 2 typical |
| Manufacturing QMS | ISO 13485:2016 | ISO 9001 typical | Variable |
| Microfluidic channel compatibility | check_circle | cancel | cancel |
| Custom formulation | check_circle | cancel | Limited |
Comparison figures from published supplier specifications, accessed 2026-09-02. Suppliers that publish no numeric endotoxin specification are shown as "Not specified".
Frequently asked questions
Common questions about FluxMPS™ DCP-RPMIGH-Q1X and its use in OoC and MPS applications.
Supporting literature
Curated peer-reviewed references relevant to OoC and MPS applications and FluxMPS™ ultra-filtered cell culture media.
- Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nature Biotechnology. 2014;32(8):760–772.doi:10.1038/nbt.2989
- Sackmann EK, Fulton AL, Beebe DJ. The present and future role of microfluidics in biomedical research. Nature. 2014;507(7491):181–189.doi:10.1038/nature13118
- Huh D, et al. Reconstituting organ-level lung functions on a chip. Science. 2010;328(5986):1662–1668.doi:10.1126/science.1188302
- Ingber DE. Is it Time for Reviewer 3 to Request Human Organ Chip Experiments Instead of Animal Validation Studies? Advanced Science. 2020;7(22):2002162.doi:10.1002/advs.202002162
- Maoz BM, et al. A linked organ-on-chip model of the human neurovascular unit reveals the metabolic landscape of brain disease. Nature Biotechnology. 2018;36:865–874.doi:10.1038/nbt.4226
- Bhise NS, et al. A liver-on-a-chip platform with bioprinted hepatic spheroids. Biofabrication. 2016;8(1):014101.doi:10.1088/1758-5090/8/1/014101
- Luni C, Serena E, Elvassore N. Human-on-chip for therapy development and fundamental science. Current Opinion in Biotechnology. 2014;25:45–50.doi:10.1016/j.copbio.2013.08.015
- Erickson KA, Bhansali S. Mycoplasma contamination in cell cultures: a survey of incidence and approaches to prevention. Journal of the Association for Laboratory Automation. 2012;17(5):346–354.doi:10.1177/2211068212456089
- van Duinen V, et al. Microfluidic 3D cell culture: from tools to tissue models. Current Opinion in Biotechnology. 2015;35:118–126.doi:10.1016/j.copbio.2015.05.002
- Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309–314.doi:10.1126/science.123.3191.309
